Compare · COAG vs TAK
COAG vs TAK
Side-by-side comparison of Hemab Therapeutics Holdings Inc. (COAG) and Takeda Pharmaceutical Company Limited (TAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. COAG focuses on Biotechnology: Biological Products (No Diagnostic Substances), while TAK focuses on Biotechnology: Pharmaceutical Preparations.
- TAK is the larger of the two at $68.79B, about 37.5x COAG ($1.84B).
- COAG has been more active in the news (8 items in the past 4 weeks vs 6 for TAK).
- TAK has more recent analyst coverage (6 ratings vs 0 for COAG).
- Company
- Hemab Therapeutics Holdings Inc.
- Takeda Pharmaceutical Company Limited
- Price
- -
- -
- Market cap
- $1.84B
- $68.79B
- 1M return
- +12.43%
- -
- 1Y return
- +14.40%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- 2018
- News (4w)
- 8
- 6
- Recent ratings
- 0
- 6
Hemab Therapeutics Holdings Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Latest COAG
- Hemab Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Hemab Therapeutics Holdings Inc.
- Hemab Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
- Amendment: SEC Form SCHEDULE 13G/A filed by Hemab Therapeutics Holdings Inc.
- Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
- Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
Latest TAK
- Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States
- President, IBU Platford Giles Richard sold $1,162,395 worth of American Depositary Shares (55,617 units at $20.90), decreasing direct ownership by 17% to 270,253 units (SEC Form 4)
- President, OBU Bitetti Teresa Marie sold $973,662 worth of American Depositary Shares (46,609 units at $20.89), decreasing direct ownership by 18% to 214,501 units (SEC Form 4)
- SEC Form 6-K filed by Takeda Pharmaceutical Company Limited
- SEC Form 6-K filed by Takeda Pharmaceutical Company Limited
- Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
- Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
- First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
- Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
- Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill